(Q47437758)

16 January 2018

title

Inflammation as a therapeutic target: a unique role for abciximab (English)

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Cardiology and cardiovascular medicine

22 March 2024

main subject

inflammation

0 references

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

22 March 2024

1

Dean J Kereiakes

1 reference

16 January 2018

language of work or name

English

0 references

publication date

1 October 2003

1 reference

16 January 2018

full work available at URL

https://api.elsevier.com/content/article/PII:S0002870303006306?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

https://api.elsevier.com/content/article/PII:S0002870303006306?httpAccept=text/plain

22 March 2024

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

22 March 2024

published in

American Heart Journal

1 reference

16 January 2018

volume

146

1 reference

16 January 2018

issue

4 Suppl

1 reference

16 January 2018

page(s)

S1-4

1 reference

16 January 2018

Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study

cites work

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.1161/01.CIR.0000025609.13806.31

Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.

1

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

The fire that burns within: C-reactive protein

22 March 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Inflammation and atherosclerosis

22 March 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Systemic inflammation in unstable angina is the result of myocardial necrosis

22 March 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial

22 March 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients

22 March 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Widespread coronary inflammation in unstable angina

22 March 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture

22 March 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina

22 March 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina

22 March 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Morphological predictors of restenosis after coronary stenting in humans

22 March 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Pathology of Acute and Chronic Coronary Stenting in Humans

22 March 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina

22 March 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study).

22 March 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Effect of statin therapy on restenosis after coronary stent implantation

22 March 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stenting

22 March 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Vastatins Inhibit Tissue Factor in Cultured Human Macrophages

22 March 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction

22 March 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Direct proinflammatory effect of C-reactive protein on human endothelial cells

22 March 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs

22 March 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein

22 March 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment

22 March 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis.

22 March 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells

22 March 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis

22 March 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization

22 March 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade

22 March 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Divergent effects of platelet-endothelial cell adhesion molecule-1 and beta 3 integrin blockade on leukocyte transmigration in vivo

22 March 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty

22 March 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Activated monocytes induce smooth muscle cell death: role of macrophage colony-stimulating factor and cell contact

22 March 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Clinical significance of increased plasma concentration of macrophage colony-stimulating factor in patients with angina pectoris

22 March 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content

22 March 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Neutrophil infiltration of culprit lesions in acute coronary syndromes

22 March 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus

22 March 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes

22 March 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy

22 March 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization

22 March 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.AHJ.2003.09.003

22 March 2024

Identifiers

1 reference

16 January 2018

1 reference

16 January 2018